Editorial Commentary
Are we really seeking for equivalence?—The virtue of the robot is in technology
Abstract
Radical cystectomy (RC) with pelvic lymph node dissection (PLND) and urinary diversion (UD) is the gold standard treatment for organ-confined muscle-invasive bladder cancer (MIBC) and recurrent non-muscle invasive disease (1). The open approach is still considered the reference option though the robot-assisted one has recently begone prevailing in western countries (2,3), mainly because of the expected advantages of this minimally-invasive technology in terms of reduced morbidity.